• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 1, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Common medication used in pregnancy may lead to obesity in children

Bioengineer by Bioengineer
March 27, 2019
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Metformin can help mothers with PCOS but can increase the risk of obesity in their children

Metformin is often used during pregnancy where the mother is suffering from polycystic ovary syndrome (PCOS). A study from the Norwegian University of Science and Technology (NTNU) has recently shown that this results in fewer miscarriages and premature births.

But a companion Norwegian study shows that children who are exposed to metformin in the womb may later have a higher risk of obesity.

“We can’t rule out that these children may have more health problems as adults,” says PhD candidate Liv Guro Engen Hanem at NTNU’s Department of Clinical and Molecular Medicine.

Hanem is the first author of an article published in the The Lancet Child & Adolescence Health journal.

The results are contrary to the researchers’ original hypothesis. They assumed that the children would have a lower risk of obesity later, due to better growth conditions in utero.

Millions of pregnant women use metformin, partly due to PCOS but most often to treat gestational diabetes. Few negative side effects have been demonstrated from its use, and none for the foetus. But so far we know little about possible long-term effects.

The results show that 8-year-old children who were exposed to metformin in utero (in the womb) on average had a higher body mass index (BMI) and waist circumference compared to children of women in a control group. This control group was given an inactive placebo instead.

A higher BMI can lead to negative effects for children later in life from obesity-related ailments.

Children born to mothers with PCOS but not exposed to metformin did not have elevated BMI, weight or height.

These children, when measured as 8-year-olds, however, did have a larger waist circumference as compared to children with mothers who did not have PCOS. Larger waist circumference is associated with an unfavourable distribution of body fat.

The article concludes by noting that the benefits of metformin use in pregnancy must be weighed against these possible long-term health problems in the offspring.

The research group examined 257 pregnant women (274 pregnancies) with PCOS during the period 2005 to 2009. The women received metformin or a placebo during pregnancy.

Researchers conducted follow-up measurements of height, weight, BMI and abdominal circumference on 141 of these children when they were 5 to 10 years old.

Metformin-exposed children were compared with placebo-exposed children. The researchers compared the placebo-exposed children (of mothers with PCOS) with children from a Norwegian reference population.

###

Hanem’s head supervisor was Professor Eszter Vanky, and co-supervisor was Associate Professor Rønnaug Ødegård, both of Department of Clinical and Molecular Medicine/NTNU. Hanem’s research work extended the PregMet1 study and was funded by the Research Council of Norway, St. Olav’s Hospital, NTNU and Novo Nordisk.

Reference: Liv Guro Engen Hanem MD, Øyvind Salvesen PhD, Petur BJuliusson MD et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial. The Lancet Child & Adolescent Health. Volume 3, Issue 3, March 2019, Pages 166-174. https://doi.org/10.1016/S2352-4642(18)30385-7

Media Contact
Eszter Vanky
[email protected]
https://geminiresearchnews.com/2019/03/common-medication-may-lead-to-obesity/

Tags: Diet/Body WeightMedicine/HealthPublic Health
Share15Tweet8Share2ShareShareShare2

Related Posts

blank

Breakthrough Discovery in Brain Receptors Could Revolutionize Next-Generation Mental Health Treatments

August 1, 2025
blank

Niclosamide Nanohybrid Trial for Mild-Moderate COVID-19

August 1, 2025

HADHA Controls JAK/STAT3 in Glioblastoma via Metabolism

August 1, 2025

Study Finds Medicare Could Cut $3.6 Billion in Costs Without Impacting Older Adults

August 1, 2025
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    37 shares
    Share 15 Tweet 9
  • Sustainability Accelerator Chooses 41 Promising Projects Poised for Rapid Scale-Up

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Breakthrough in Melanoma Guidance System Offers New Hope to Halt Metastasis

SFU Researchers Unveil Innovative Tool for Enhanced Blender-Style Lighting Control in Photographs

Breakthrough Discovery in Brain Receptors Could Revolutionize Next-Generation Mental Health Treatments

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.